Skip to main navigation Skip to search Skip to main content

Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents

  • Linyi Wei
  • , Qian Shi
  • , Kenneth F. Bastow
  • , Arnold Brossi
  • , Susan L. Morris-Natschke
  • , Kyoko Nakagawa-Goto
  • , Tian Shung Wu
  • , Shiow Lin Pan
  • , Che Ming Teng
  • , Kuo Hsiung Lee

Research output: Contribution to journalArticlepeer-review

Abstract

C9-Substituted phenanthrene-based tylophorine derivatives (PBTs) (13-36) were synthesized and evaluated as in vitro anticancer agents against the human A549 lung cancer cell line. Twelve active compounds were further examined against DU-145 (prostate), ZR-751 (breast), KB (nasopharyngeal), and KB-Vin (multidrug resistant KB subline) human cancer cell lines. They showed potent cytotoxic activity against both wild type and matched multidrug resistant KB cell lines, and displayed notable selectivity toward DU-145 (prostate) and ZR-751 (breast) cancer cell lines. The mode of action of this class may be distinctly different from that of other cancer chemotherapeutic compounds. Three PBT analogs were also evaluated in a murine model. Compound 24b showed modest in vivo antitumor activity against human A549 xenograft in nude mice as well as potent in vitro cytotoxic activity, and thus, is a promising anticancer lead compound.

Original languageEnglish
Pages (from-to)3674-3680
Number of pages7
JournalJournal of Medicinal Chemistry
Volume50
Issue number15
DOIs
Publication statusPublished - Jul 26 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents'. Together they form a unique fingerprint.

Cite this